BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21220606)

  • 1. Pyoderma gangrenosum with the use of sunitinib.
    Nadauld LD; Miller MB; Srinivas S
    J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of pyoderma gangrenosum possibly associated with sunitinib treatment.
    Ueharaguchi Y; Kabashima K; Sasahashi M; Matsuda A; Matubara K; Matsui M
    Int J Dermatol; 2013 May; 52(5):634-6. PubMed ID: 23590380
    [No Abstract]   [Full Text] [Related]  

  • 3. [Sunitinib-induced pyoderma gangrenosum].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 Dec; 140(12):841-2. PubMed ID: 24315238
    [No Abstract]   [Full Text] [Related]  

  • 4. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.
    De Vincenzo F; Zucali PA; Ceresoli GL; Colombo P; Simonelli M; Lorenzi E; Perrino M; Gianoncelli L; De Sanctis R; Graziotti P; Santoro A
    J Clin Oncol; 2011 Jun; 29(18):e529-31. PubMed ID: 21483010
    [No Abstract]   [Full Text] [Related]  

  • 6. Lower limbs erosions induced by sunitinib.
    Kluger N; Chapelle A; Jacot W; Guillot B
    Acta Derm Venereol; 2011 May; 91(3):360-1. PubMed ID: 21103845
    [No Abstract]   [Full Text] [Related]  

  • 7. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib?
    ten Freyhaus K; Homey B; Bieber T; Wilsmann-Theis D
    Br J Dermatol; 2008 Jul; 159(1):242-3. PubMed ID: 18489600
    [No Abstract]   [Full Text] [Related]  

  • 8. Pyoderma Gangrenosum Associated with Sunitinib: A Case Report.
    Sevimli Dikicier B
    Adv Skin Wound Care; 2019 Sep; 32(9):427-429. PubMed ID: 31408027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performing cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective.
    Shaw GL; Hussain M; Nair R; Bycroft J; Beltran L; Green JS; Powles T; Peters JL
    Urol Int; 2012; 89(1):83-8. PubMed ID: 22614181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma.
    Edeline J; Laguerre B; Rolland Y; Patard JJ
    Ann Oncol; 2010 Jan; 21(1):186-7. PubMed ID: 19875754
    [No Abstract]   [Full Text] [Related]  

  • 11. Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?
    Winn SK; Ellis S; Savage P; Sampson S; Marsh JE
    Nephrol Dial Transplant; 2009 Feb; 24(2):673-5. PubMed ID: 19039026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary artery thrombosis mimicking disease progression in metastatic renal cell carcinoma on Sunitinib.
    Ahmad M; Prasad S; Krishna MV; Lavingia V
    Indian J Cancer; 2016; 53(1):112-3. PubMed ID: 27146756
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute cardiac failure after sunitinib.
    Machiels JP; Bletard N; Pirenne P; Jacquet L; Bonbled F; Duck L
    Ann Oncol; 2008 Mar; 19(3):597-9. PubMed ID: 18272908
    [No Abstract]   [Full Text] [Related]  

  • 14. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
    J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
    Ayllon J; Beuselinck B; Morel A; Barrascout E; Medioni J; Scotte F; Oudard S
    Cancer Invest; 2011 May; 29(4):282-5. PubMed ID: 21469976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
    Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
    Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib-induced pyoderma gangrenosum-like skin ulcer.
    Kuntz T; Koushk-Jalali B; Kreuter A
    CMAJ; 2020 May; 192(20):E552. PubMed ID: 32452467
    [No Abstract]   [Full Text] [Related]  

  • 18. Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma.
    Ballardini P; Margutti G; Aliberti C; Manfredini R
    Clin Drug Investig; 2009; 29(7):487-490. PubMed ID: 19499966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exfoliative esophagitis in a patient with metastatic renal cell carcinoma during sunitinib treatment.
    Huang J; Wang T; Huang Y
    Med Oncol; 2013 Mar; 30(1):436. PubMed ID: 23283650
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.